LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Evolent Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.96 -1.98

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.88

Max

4.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

30M

-21M

Pardavimai

35M

480M

Pelno marža

-4.351

Darbuotojai

4,500

EBITDA

512K

15M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+150.99% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-302M

478M

Ankstesnė atidarymo kaina

5.94

Ankstesnė uždarymo kaina

3.96

Naujienos nuotaikos

By Acuity

40%

60%

131 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Evolent Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-18 23:54; UTC

Karštos akcijos

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025-12-18 23:51; UTC

Uždarbis

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025-12-18 23:39; UTC

Pagrindinės rinkos jėgos

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025-12-18 21:40; UTC

Uždarbis

Nike Sales Tick Up, But China Weakness Persists

2025-12-18 23:45; UTC

Rinkos pokalbiai

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025-12-18 23:37; UTC

Rinkos pokalbiai
Uždarbis

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025-12-18 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025-12-18 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025-12-18 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025-12-18 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025-12-18 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025-12-18 22:58; UTC

Įsigijimai, susijungimai, perėmimai

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025-12-18 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025-12-18 22:55; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:59; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-18 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-18 21:35; UTC

Uždarbis

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-18 21:31; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev Down 17% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q EPS 53c >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Apparel Rev $3.91B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Equipment Rev $550M >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q N Amer Rev $5.63B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Footwear Rev $7.66B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev $1.42B >NKE

Akcijų palyginimas

Kainos pokytis

Evolent Health Inc Prognozė

Kainos tikslas

By TipRanks

150.99% į viršų

12 mėnesių prognozė

Vidutinis 10.14 USD  150.99%

Aukščiausias 16 USD

Žemiausias 7 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Evolent Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

13

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

10.33 / 10.95Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

131 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Evolent Health Inc

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
help-icon Live chat